The resistance of monocytic AML cells to therapeutic targeting of Bcl-2 with the selective inhibitor venetoclax is the best characterized example of differentiation-associated treatment resistance that also involves differences in metabolism (Table 4). This evidence concerns the gene BCL2 and acute myeloid leukemia.